Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (4609)	11/1/2017 12:34:49 PM
From: richardred	1 Recommendation Recommended By The Ox Read Replies (1) \| Respond to of 7120

I'm not expecting anything , but negative on the earnings release tomorrow. Today's action kind of implies that. I still see value here. This company will be in transition. There's a new CEO. A pharma guy. The current CFO will also be leaving here to. I've been doing a little bit of homework here. The sum of what the company paid just to enter the generic business is worth more than the total market cap. of just of 300 million. Bearing in mind I'm speculating. I think this make a good case for separating performance chemicals from generics. This leading to a stronger stock price in due time. Although painful short term. I can hold this one and dollar cost average because it does pay a dividend . IMO it's not overpriced to forward earnings. The Near term appeal might be separating into two companies. IMO the company stumbled on their last acquisition. However I believe the company also acquired a good pipeline of generics waiting for future approval. P.S. Tomorrow could be a chance for a big drop with lag to follow. PRGO is selling now at less than half what MYLN offered. I couldn't believe at the time they rejected the offer.